Reyon Pharmaceutical Co Ltd (102460) — Cash Flow-to-Debt Ratio
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of ₩-1.73 Billion could theoretically repay 0% of its total liabilities (₩239.99 Billion) in one year. See cash generation quality of Reyon Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Reyon Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2008–2024)
Historical debt coverage capacity for Reyon Pharmaceutical Co Ltd across 13 annual periods. Also explore 102460 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Reyon Pharmaceutical Co Ltd (2008–2024)
Year-by-year debt coverage analysis for Reyon Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Reyon Pharmaceutical Co Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-1.44 Billion | ₩250.05 Billion | ▼ -116.7% |
| 2023 | 0.03x | ₩8.65 Billion | ₩251.15 Billion | ▼ -6.6% |
| 2022 | 0.04x | ₩8.73 Billion | ₩236.93 Billion | ▼ -26.6% |
| 2021 | 0.05x | ₩11.68 Billion | ₩232.74 Billion | ▼ -4.5% |
| 2020 | 0.05x | ₩4.60 Billion | ₩87.52 Billion | ▲ +122.5% |
| 2019 | -0.23x | ₩-12.18 Billion | ₩52.19 Billion | ▼ -258.6% |
| 2018 | 0.15x | ₩11.45 Billion | ₩77.77 Billion | ▼ -37.5% |
| 2017 | 0.24x | ₩16.76 Billion | ₩71.18 Billion | ▼ -24.3% |
| 2016 | 0.31x | ₩9.47 Billion | ₩30.44 Billion | ▼ -61.4% |
| 2012 | 0.81x | ₩24.65 Billion | ₩30.57 Billion | ▲ +51.0% |
| 2011 | 0.53x | ₩15.34 Billion | ₩28.73 Billion | ▲ +36.2% |
| 2009 | 0.39x | ₩8.68 Billion | ₩22.15 Billion | ▲ +48.2% |
| 2008 | 0.26x | ₩5.99 Billion | ₩22.64 Billion | — |